4.6 Letter

Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'

期刊

NATURE REVIEWS CLINICAL ONCOLOGY
卷 15, 期 4, 页码 -

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/nrclinonc.2018.20

关键词

-

类别

资金

  1. Bristol-Myers Squibb
  2. Celgene
  3. Cellectis
  4. Kite Pharma
  5. Merck
  6. Poseida Therapeutics
  7. Janssen
  8. Abbvie
  9. ADC Therapeutics
  10. Genentech
  11. Incyte
  12. Pharmacyclics
  13. Pfizer
  14. Seattle Genetics
  15. Servier
  16. Verastem
  17. Daichi-Sanky
  18. Karyopharm
  19. Sunesis

向作者/读者索取更多资源

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Critical Care Medicine

TEMPERATURE TRAJECTORY SUB-PHENOTYPES AND THE IMMUNO-INFLAMMATORY RESPONSE IN PEDIATRIC SEPSIS

Nadir Yehya, Julie C. Fitzgerald, Katie Hayes, Donglan Zhang, Jenny Bush, Natalka Koterba, Fang Chen, Florin Tuluc, David T. Teachey, Fran Balamuth, Simon F. Lacey, Jan Joseph Melenhorst, Scott L. Weiss

Summary: Trajectory-defined sub-phenotypes based on temperature can help categorize critically ill septic children, with hypothermic patients exhibiting lower levels of inflammatory cytokines and chemokines.
Article Oncology

A simple additive staging system for newly diagnosed multiple myeloma

Nadine H. Abdallah, Moritz Binder, S. Vincent Rajkumar, Patricia T. Greipp, Prashant Kapoor, Angela Dispenzieri, Morie A. Gertz, Linda B. Baughn, Martha Q. Lacy, Suzanne R. Hayman, Francis K. Buadi, David Dingli, Ronald S. Go, Yi L. Hwa, Amie L. Fonder, Miriam A. Hobbs, Yi Lin, Nelson Leung, Taxiarchis Kourelis, Rahma Warsame, Mustaqeem A. Siddiqui, Robert A. Kyle, P. Leif Bergsagel, Rafael Fonseca, Rhett P. Ketterling, Shaji K. Kumar

Summary: Risk stratification is crucial in multiple myeloma for predicting prognosis, selecting patients for clinical trials, and comparing treatment approaches. A new staging system has been developed that incorporates additional high-risk disease features and improves upon the current risk stratification system. This system is easy to implement and provides valuable prognostic information.

BLOOD CANCER JOURNAL (2022)

Article Hematology

Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma

Joselle Cook, Kah-Whye Peng, Thomas E. Witzig, Stephen M. Broski, Jose C. Villasboas, Jonas Paludo, Mrinal Patnaik, Vincent Rajkumar, Angela Dispenzieri, Nelson Leung, Francis Buadi, Nora Bennani, Stephen M. Ansell, Lianwen Zhang, Nandakumar Packiriswamy, Baskar Balakrishnan, Bethany Brunton, Marissa Giers, Brenda Ginos, Amylou C. Dueck, Susan Geyer, Morie A. Gertz, Rahma Warsame, Ronald S. Go, Suzanne R. Hayman, David Dingli, Shaji Kumar, Leif Bergsagel, Javier L. Munoz, Wilson Gonsalves, Taxiarchis Kourelis, Eli Muchtar, Prashant Kapoor, Robert A. Kyle, Yi Lin, Mustaqeem Siddiqui, Amie Fonder, Miriam Hobbs, Lisa Hwa, Shruthi Naik, Stephen J. Russell, Martha Q. Lacy

Summary: This study investigated the safety and efficacy of intravenous oncolytic virotherapy in patients with relapsed/refractory hematologic malignancies. The results showed that VSV-IFN beta-NIS had significant therapeutic effects in patients with TCL, possibly through a combination of oncolytic tumor destruction and immune response.

BLOOD ADVANCES (2022)

Letter Hematology

Peak absolute lymphocyte count after CAR-T infusion predicts clinical response in aggressive lymphoma

Radhika Bansal, Mattia Novo, Abdullah S. Al Saleh, Anatilde Gonzalez Guerrico, Henan Zhang, Zuoyi Shao, Elham Babadi, Kodi E. Martinez, Gabrielle A. McCoy, Matthew A. Hathcock, Arushi Khurana, Nabila Nora Bennani, Jonas Paludo, Yucai Wang, Stephen M. Ansell, Patrick B. Johnston, Jose C. Villasboas, Yi Lin

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Article Hematology

Inhibition of the Sec61 translocon overcomes cytokine-induced glucocorticoid resistance in T-cell acute lymphoblastic leukaemia

Lauren K. Meyer, Cristina Delgado-Martin, Phillip P. Sharp, Benjamin J. Huang, Dustin McMinn, Tiffaney L. Vincent, Theresa Ryan, Terzah M. Horton, Brent L. Wood, David T. Teachey, Jack Taunton, Christopher J. Kirk, Michelle L. Hermiston

Summary: In this study, it was found that a novel Sec61 inhibitor, KZR-445, can overcome glucocorticoid resistance in T-cell acute lymphoblastic leukemia (T-ALL) and attenuate the dexamethasone-induced increase in cell surface IL-7R. This finding is of significant importance in addressing glucocorticoid resistance.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Article Oncology

Sex-based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children's Oncology Group report

Sumit Gupta, David T. Teachey, Zhiguo Chen, Karen R. Rabin, Kimberly P. Dunsmore, Eric C. Larsen, Kelly W. Maloney, Leonard A. Mattano, Stuart S. Winter, Andrew J. Carroll, Nyla A. Heerema, Michael J. Borowitz, Brent L. Wood, William L. Carroll, Elizabeth A. Raetz, Naomi J. Winick, Mignon L. Loh, Stephen P. Hunger, Meenakshi Devidas

Summary: Boys with acute lymphoblastic leukemia continue to have lower survival rates compared to girls. This study found that the sex-based disparities still exist in contemporary therapy, with boys experiencing inferior event-free survival and overall survival, primarily due to higher rates of relapse, particularly involving the central nervous system.

CANCER (2022)

Review Oncology

Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma

Arushi Khurana, Yi Lin

Summary: Allogeneic CAR-T therapies have advantages over autologous CAR-T therapies, such as easier accessibility and more stable quality, but they also have complications and require genomic editing. Further research and clinical trials are needed.

CURRENT TREATMENT OPTIONS IN ONCOLOGY (2022)

Article Oncology

JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia

Kimberly Bodaar, Natsuko Yamagata, Anais Barthe, Jack Landrigan, Triona Ni Chonghaile, Melissa Burns, Kristen E. Stevenson, Meenakshi Devidas, Mignon L. Loh, Stephen P. Hunger, Brent Wood, Lewis B. Silverman, David T. Teachey, Jules P. Meijerink, Anthony Letai, Alejandro Gutierrez

Summary: Resistance to mitochondrial apoptosis is associated with activating mutations of JAK3 in patients with diverse tumor types, including T-ALL. Inhibition of JAK3 reverses the apoptotic blockade and shows synergy with glucocorticoids in JAK3-mutant T-ALL.

LEUKEMIA (2022)

Article Oncology

Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

Thomas Martin, Saad Z. Usmani, Jesus G. Berdeja, Mounzer Agha, Adam D. Cohen, Parameswaran Hari, David Avigan, Abhinav Deol, Myo Htut, Alexander Lesokhin, Nikhil C. Munshi, Elizabeth O'Donnell, A. Keith Stewart, Jordan M. Schecter, Jenna D. Goldberg, Carolyn C. Jackson, Tzu-Min Yeh, Arnob Banerjee, Alicia Allred, Enrique Zudaire, William Deraedt, Yunsi Olyslager, Changwei Zhou, Lida Pacaud, Deepu Madduri, Andrzej Jakubowiak, Yi Lin, Sundar Jagannath

Summary: PURPOSECARTITUDE-1, a phase Ib/II study, evaluated the safety and efficacy of Ciltacabtagene Autoleucel in heavily treated patients with relapsed/refractory multiple myeloma. The study showed early, deep, and durable responses at 12 months, with updated results at 2 years. Patients received a single infusion of Ciltacabtagene Autoleucel and responses were assessed.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Biochemistry & Molecular Biology

Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial

Yi Lin, Noopur S. Raje, Jesus G. Berdeja, David S. Siegel, Sundar Jagannath, Deepu Madduri, Michaela Liedtke, Jacalyn Rosenblatt, Marcela V. Maus, Monica Massaro, Fabio Petrocca, Ashish Yeri, Olivia Finney, Andrea Caia, Zhihong Yang, Nathan Martin, Timothy B. Campbell, Julie Rytlewski, Jaymes Fuller, Kristen Hege, Nikhil C. Munshi, James N. Kochenderfer

Summary: This study conducted a post hoc analysis of the use of Idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma and found that it is safe and well-tolerated, with a positive impact on response rates. Additionally, the study identified a correlation between the state of T cells and durable responses.

NATURE MEDICINE (2023)

Article Hematology

Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities

Uday R. Popat, Oren Pasvolsky, Roland Bassett Jr, Rohtesh S. Mehta, Amanda Olson, Julianne Chen, Amin M. Alousi, Gheath Al-Atrash, Qaiser Bashir, Alison M. Gulbis, Chitra M. Hosing, Jin S. Im, Partow Kebriaei, Issa Khouri, David Marin, Yago Nieto, Betul Oran, Neeraj Saini, Terri Lynn Shigle, Samer A. Srour, Jeremy L. Ramdial, Katayoun Rezvani, Muzaffar H. Qazilbash, Borje S. Andersson, Richard E. Champlin, Elizabeth J. Shpall

Summary: A fractionated myeloablative busulfan regimen was found to be effective in reducing nonrelapse mortality without increasing relapse rate for patients undergoing allogeneic hematopoietic cell transplantation, especially for older patients and those with comorbidities.

BLOOD ADVANCES (2023)

Article Hematology

Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States

Caron A. Jacobson, Frederick L. Locke, Long Ma, Julius Asubonteng, Zhen-Huan Hu, Tanya Siddiqi, Sairah Ahmed, Armin Ghobadi, David Bernard Miklos, Yi Lin, Miguel-Angel Perales, Matthew Alexander Lunning, Megan M. Herr, Brian T. Hill, Siddhartha Ganguly, Hua Dong, Sarah Nikiforow, Michele Hooper, Jun Kawashima, Hairong Xu, Marcelo C. Pasquini

Summary: This study evaluated the outcomes of axi-cel therapy in real-world settings. The results showed that patients ineligible for the ZUMA-1 trial had durable responses with axi-cel treatment. Despite higher rates of side effects, elderly patients had favorable efficacy outcomes.

TRANSPLANTATION AND CELLULAR THERAPY (2022)

Letter Pharmacology & Pharmacy

Response to Letters to the Editor: Assessment of attrition and retention factors in the oncology pharmacy workforce: Results of the oncology pharmacy workforce survey

Kamakshi V. Rao, Alison M. Gulbis, Zahra Mahmoudjafari

JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY (2022)

Article Hematology

Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant

Surbhi Sidana, Amylou C. Dueck, Gita Thanarajasingam, Joan M. Griffin, Carrie Thompson, Urshila Durani, Michelle Burtis, Rahma Warsame, Jonas Paludo, Morie A. Gertz, Angela Dispenzieri, Stephen M. Ansell, S. Vincent Rajkumar, Kathleen Yost, Nora Bennani, Yi Lin, Shaji Kumar

Summary: Limited data on patient experience after CAR-T cell therapy, especially compared to autologous and allogeneic transplantation. Prospective evaluation of patient-reported QoL, symptom burden and cognition after CAR-T therapy compared to autoSCT and alloSCT. Short-term QoL, including physical and functional domains, was better in the CAR-T group, but all groups experienced an initial decline coinciding with peak symptoms. These findings serve as a guide for patient education, symptom management, and future studies in CAR-T cell therapy.

TRANSPLANTATION AND CELLULAR THERAPY (2022)

Article Pharmacology & Pharmacy

Assessment of attrition and retention factors in the oncology pharmacy workforce: Results of the oncology pharmacy workforce survey

Kamakshi Rao, Alison M. Gulbis, Zahra Mahmoudjafari

Summary: Hospital departments of pharmacy are facing challenges in recruiting and retaining trained hematology-oncology pharmacists, with the growing attrition of clinically-trained pharmacists being a consistent challenge. A survey of oncology pharmacists in the United States revealed that the workforce is highly trained and capable, with a high level of satisfaction. However, over 60% of respondents were actively seeking or open to alternate employment outside of the patient care environment. Factors contributing to attrition risk include work burdens, burnout, lack of work-life integration, and ineffective leadership. Commitments to clinical work were associated with improved job satisfaction and decreased attrition risk.

JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY (2022)

暂无数据